Pramlintide vs Tirzepatide

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

Pramlintide

Pramlintide (Symlin) is a synthetic analog of amylin, FDA-approved as an adjunct to insulin therapy in type 1 and type 2 diabetes. It helps control post-meal blood sugar spikes and promotes modest weight loss.

Full details →

Tirzepatide

Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight loss), it has shown superior weight loss results compared to semaglutide in clinical trials.

Full details →

Side-by-Side Comparison

AspectPramlintideTirzepatide
MechanismMimics amylin's effects: slows gastric emptying, suppresses glucagon secretion after meals, and promotes satiety through central mechanisms. Complements insulin therapy.Activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, providing synergistic effects on insulin secretion, appetite suppression, and metabolic regulation. The dual mechanism may explain its enhanced efficacy.
Typical DosageType 1: Start 15mcg before meals, titrate to 30-60mcg. Type 2: Start 60mcg, may increase to 120mcg. Always with meal containing 30+ grams carbs or 250+ calories.Start at 2.5mg weekly, titrate every 4 weeks through 5mg, 7.5mg, 10mg, 12.5mg, to maximum 15mg weekly. Full titration takes approximately 20 weeks.
AdministrationSubcutaneous injection immediately before major meals. Must reduce mealtime insulin by 50% when starting to prevent hypoglycemia. Never mix with insulin.Subcutaneous injection once weekly. Rotate injection sites. Slower titration may help reduce GI side effects.
Side EffectsNausea (very common initially), headache, anorexia, vomiting, and abdominal pain. GI effects typically improve over time.Similar to semaglutide: nausea, diarrhea, vomiting, constipation, abdominal pain, decreased appetite. Generally improve with continued use.
Best For

What They Have in Common

Both Pramlintide and Tirzepatide are commonly used for:

Ready to Learn More?